Literature DB >> 9343159

Identification of envelope protein residues required for the expanded host range of 10A1 murine leukemia virus.

J Y Han1, P M Cannon, K M Lai, Y Zhao, M V Eiden, W F Anderson.   

Abstract

The 10A1 murine leukemia virus (MuLV) is a recombinant type C retrovirus isolated from a mouse infected with amphotropic MuLV (A-MuLV). 10A1 and A-MuLV have 91% amino acid identity in their envelope proteins yet display different host ranges. For example, CHO-K1 cells are resistant to A-MuLV but susceptible to infection by 10A1. We have now determined that retroviral vectors bearing altered A-MuLV envelope proteins containing 10A1-derived residues at positions 71 (A71G), 74 (Q74K), and 139 (V139M) transduce CHO-K1 cells at efficiencies similar to those achieved with 10A1 enveloped vectors. A-MuLV enveloped retroviral vectors with these three 10A1 residues were also able to transduce A-MuLV-infected NIH 3T3 cells. This observation is consistent with the ability of vectors bearing this altered A-MuLV envelope protein to recognize the 10A1-specific receptor present on NIH 3T3 cells and supports the possibility that residues at positions 71, 74, and 139 of the 10A1 envelope SU protein account for the expanded host range of 10A1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9343159      PMCID: PMC192265     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

Review 1.  Retrovirus envelope glycoproteins.

Authors:  E Hunter; R Swanstrom
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Improved retroviral vectors for gene transfer and expression.

Authors:  A D Miller; G J Rosman
Journal:  Biotechniques       Date:  1989-10       Impact factor: 1.993

3.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

4.  Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase.

Authors:  S Goff; P Traktman; D Baltimore
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

5.  Interference grouping of murine leukemia viruses: a distinct receptor for the MCF-recombinant viruses in mouse cells.

Authors:  A Rein
Journal:  Virology       Date:  1982-07-15       Impact factor: 3.616

6.  Receptor interference groups of 20 retroviruses plating on human cells.

Authors:  M A Sommerfelt; R A Weiss
Journal:  Virology       Date:  1990-05       Impact factor: 3.616

7.  Sequence analysis of amphotropic and 10A1 murine leukemia viruses: close relationship to mink cell focus-inducing viruses.

Authors:  D Ott; R Friedrich; A Rein
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

8.  Tunicamycin treatment of CHO cells abrogates multiple blocks to retrovirus infection, one of which is due to a secreted inhibitor.

Authors:  D G Miller; A D Miller
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

9.  Different recombinant murine leukemia viruses use different cell surface receptors.

Authors:  A Rein; A Schultz
Journal:  Virology       Date:  1984-07-15       Impact factor: 3.616

10.  Characterization of a highly oncogenic murine leukemia virus from wild mice.

Authors:  S Rasheed; B K Pal; M B Gardner
Journal:  Int J Cancer       Date:  1982-03-15       Impact factor: 7.396

View more
  27 in total

1.  Identification of the block in targeted retroviral-mediated gene transfer.

Authors:  Y Zhao; L Zhu; S Lee; L Li; E Chang; N W Soong; D Douer; W F Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 2.  Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.

Authors:  J Overbaugh; A D Miller; M V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

3.  Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection.

Authors:  L Li; J M Olvera; K E Yoder; R S Mitchell; S L Butler; M Lieber; S L Martin; F D Bushman
Journal:  EMBO J       Date:  2001-06-15       Impact factor: 11.598

4.  Efficient cell infection by Moloney murine leukemia virus-derived particles requires minimal amounts of envelope glycoprotein.

Authors:  E Bachrach; M Marin; M Pelegrin; G Karavanas; M Piechaczyk
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  G100R mutation within 4070A murine leukemia virus Env increases virus receptor binding, kinetics of entry, and viral transduction efficiency.

Authors:  Chi-Wei Lu; Lucille O'Reilly; Monica J Roth
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  A comprehensive approach to mapping the interacting surfaces of murine amphotropic and feline subgroup B leukemia viruses with their cell surface receptors.

Authors:  C S Tailor; A Nouri; D Kabat
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Identification of envelope determinants of feline leukemia virus subgroup B that permit infection and gene transfer to cells expressing human Pit1 or Pit2.

Authors:  J Sugai; M Eiden; M M Anderson; N Van Hoeven; C D Meiering; J Overbaugh
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 8.  Library screening and receptor-directed targeting of gammaretroviral vectors.

Authors:  Peter M Mazari; Monica J Roth
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

9.  Functional domains in the retroviral transmembrane protein.

Authors:  Y Zhao; L Zhu; C A Benedict; D Chen; W F Anderson; P M Cannon
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Characterization of the proline-rich region of murine leukemia virus envelope protein.

Authors:  B Weimin Wu; P M Cannon; E M Gordon; F L Hall; W F Anderson
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.